Analysts Set NewLink Genetics Corporation (NLNK) Price Target at $25.83
Shares of NewLink Genetics Corporation (NASDAQ:NLNK) have earned an average rating of “Buy” from the eight analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $25.67.
A number of research analysts recently commented on the company. Jefferies Group LLC lowered their price objective on NewLink Genetics Corporation from $26.00 to $25.00 and set a “buy” rating for the company in a research note on Friday. Stifel Nicolaus upped their price objective on NewLink Genetics Corporation from $25.00 to $29.00 and gave the stock a “buy” rating in a research note on Friday. Cantor Fitzgerald restated a “buy” rating and set a $26.00 price objective on shares of NewLink Genetics Corporation in a research note on Thursday. Bank of America Corporation assumed coverage on NewLink Genetics Corporation in a research note on Friday, October 13th. They set a “buy” rating and a $22.00 price objective for the company. Finally, ValuEngine downgraded NewLink Genetics Corporation from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 26th.
Shares of NewLink Genetics Corporation (NASDAQ:NLNK) traded up $0.30 on Thursday, reaching $8.87. The company had a trading volume of 1,340,294 shares, compared to its average volume of 1,432,581. NewLink Genetics Corporation has a 52-week low of $5.90 and a 52-week high of $25.17.
TRADEMARK VIOLATION NOTICE: This report was first posted by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.watchlistnews.com/analysts-set-newlink-genetics-corporation-nlnk-price-target-at-25-83/1681004.html.
In other NewLink Genetics Corporation news, major shareholder Stine Seed Farm, Inc. purchased 780,487 shares of the firm’s stock in a transaction dated Friday, October 6th. The stock was bought at an average price of $10.25 per share, with a total value of $7,999,991.75. Following the completion of the purchase, the insider now owns 7,857,732 shares in the company, valued at approximately $80,541,753. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 13.70% of the company’s stock.
Several large investors have recently added to or reduced their stakes in NLNK. Candriam Luxembourg S.C.A. grew its stake in shares of NewLink Genetics Corporation by 337.3% in the third quarter. Candriam Luxembourg S.C.A. now owns 328,000 shares of the biotechnology company’s stock worth $3,339,000 after purchasing an additional 253,000 shares in the last quarter. Columbus Circle Investors boosted its stake in NewLink Genetics Corporation by 72.5% during the second quarter. Columbus Circle Investors now owns 591,765 shares of the biotechnology company’s stock valued at $4,349,000 after buying an additional 248,724 shares in the last quarter. Ameriprise Financial Inc. bought a new position in NewLink Genetics Corporation during the first quarter valued at about $3,453,000. American Century Companies Inc. bought a new position in NewLink Genetics Corporation during the third quarter valued at about $963,000. Finally, Quantitative Investment Management LLC bought a new position in NewLink Genetics Corporation during the second quarter valued at about $635,000. 55.09% of the stock is owned by institutional investors.
About NewLink Genetics Corporation
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.